The expression of androgen-responsive genes is up-regulated in the epithelia of benign prostatic hyperplasia

Prostate

Volumn 69, Issue 16, 2009, Pages 1716-1723

  O'Malley, Katherine J ^a   Dhir, Rajiv ^a,b   Nelson, Joel B ^a,b   Bost, James ^a   Lin, Yan ^b   Wang, Zhou ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Androgen responsive genes; Androgens; BPH; Human

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CONTROLLED STUDY; ELEVEN NINETEEN LYSINE RICH LEUKEMIA ASSOCIATED FACTOR 2; ELEVEN NINETEEN LYSINE RICH LEUKEMIA GENE 2; EPITHELIUM CELL; FKBP5 GENE; GENE; HUMAN; HUMAN TISSUE; LASER MICRODISSECTION; MALE; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION; RNA ISOLATION; UPREGULATION;

ANDROGENS; EPITHELIAL CELLS; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REFERENCE VALUES; SIGNAL TRANSDUCTION; TACROLIMUS BINDING PROTEINS; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ELONGATION FACTORS; UP-REGULATION;

EID: 70350437986     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21034     Document Type: Article

References (51)

1. Roehrborn CG, McConnell JD. Benign prostatic hyperplasia: Etiology, pathophysiology, epidemiology, and natural history. Campbell-Walsh Urology, Vol.9. Philadelphia: Saunders Elsevier; 2007.
2. Lee C, Kozlowski JM, Grayhack JT. Etiology of benign prostatic hyperplasia. Urol Clin North Am 1995;22(2):237-246.
3. Berry S, Coffey D, Walsh P, Ewing L. The development of human benign prostatic hyperplasia with age. J Urol 1984;132(3):474-479. (Pubitemid 14026148)
4. Greco KA, McVary KT. The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res 2008;20(Suppl 3):S33-S43.
5. McVary KT. BPH: Epidemiology and comorbidities. Am J Manag Care 2006;12 (5 Suppl):S122-S128.
6. Weis KA, Epstein RS, Huse DM, Deverka PA, Oster G. The costs of prostatectomy for benign prostatic hyperplasia. Prostate 1993;22(4):325-334. (Pubitemid 23176274)
7. Kortt MA, Bootman JL. The economics of benign prostatic hyperplasia treatment: A literature review. Clin Ther 1996;18(6): 1227-1241. (Pubitemid 27077126)
8. Penson DF, Chan JM. Prostate cancer. J Urol 2007;177(6):2020-2029.
9. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 1989;2:33-50. (Pubitemid 20075619)
10. McNeal J. Pathology of benign prostatic hyperplasia. Insight into etiology. Urol Clin North Am 1990;17(3):477-486.
11. Fromont G, Chene L, Latil A, Bieche I, Vidaud M, Vallancien G, Mangin P, Fournier G, Validire P, Cussenot O. Molecular profiling of benign prostatic hyperplasia using a large scale real-time reverse transcriptase-polymerase chain reaction approach. J Urol 2004;172(4 Pt 1):1382-1385. (Pubitemid 39249725)
12. Luo J, Dunn T, Ewing C, Sauvageot J, Chen Y, Trent J, Isaacs W. Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis. Prostate 2002;51(3): 189-200. (Pubitemid 34492640)
13. Cazares LH, Adam BL, Ward MD, Nasim S, Schellhammer PF, Semmes OJ, Wright GL Jr. Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ ionization mass spectrometry. Clin Cancer Res 2002;8(8):2541-2552. (Pubitemid 34856338)
14. Bauman DR, Steckelbroeck S, Peehl DM, Penning TM. Transcript profiling of the androgen signal in normal prostate, benign prostatic hyperplasia, and prostate cancer. Endocrinology 2006; 147(12):5806-5816. (Pubitemid 44833497)
15. Marcelli M, Cunningham GR. Hormonal signaling in prostatic hyperplasia and neoplasia. J Clin Endocrinol Metab 1999;84(10): 3463-3468. (Pubitemid 30645192)
16. Coffey DS, Walsh PC. Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin North Am 1990;17(3): 461-475. (Pubitemid 20220190)
17. Kim J, Coetzee GA. Prostate specific antigen gene regulation by androgen receptor. J Cell Biochem 2004;93(2):233-241. (Pubitemid 44264201)
18. Loeb S, Catalona WJ. Prostate-specific antigen in clinical practice. Cancer Lett 2007;249(1):30-39.
19. Clegg N, Eroglu B, Ferguson C, Arnold H, Moorman A, Nelson PS. Digital expression profiles of the prostate androgen-response program. J Steroid Biochem Mol Biol 2002;80(1):13-23. (Pubitemid 34178407)
20. Magee JA, Chang LW, Stormo GD, Milbrandt J. Direct, androgen receptor-mediated regulation of the FKBP5 gene via a distal enhancer element. Endocrinology 2006;147(1):590-598. (Pubitemid 43004313)
21. Shilatifard A, Duan DR, Haque D, Florence C, Schubach WH, Conaway JW, Conaway RC. ELL2, a new member of an ELL family of RNA polymerase II elongation factors. Proc Natl Acad Sci USA 1997;94(8):3639-3643. (Pubitemid 27180425)
22. Bolton EC, So AY, Chaivorapol C, Haqq CM, Li H, Yamamoto KR. Cell- and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev 2007;21(16):2005-2017. (Pubitemid 47267287)
23. Simone F, Luo RT, Polak PE, Kaberlein JJ, Thirman MJ. ELL-associated factor 2 (EAF2), a functional homolog of EAF1 with alternative ELL binding properties. Blood 2003;101(6):2355-2362. (Pubitemid 36302081)
24. Kong SE, Banks CA, Shilatifard A, Conaway JW, Conaway RC. ELL-associated factors 1 and 2 are positive regulators of RNA polymerase II elongation factor ELL. Proc Natl Acad Sci USA 2005;102(29):10094-10098. (Pubitemid 41023331)
25. Xiao W, Jiang F, Wang Z. ELL binding regulates U19/Eaf2 intracellular localization, stability, and transactivation. Prostate 2006;66(1):1-12. (Pubitemid 43005944)
26. Xiao W, Zhang Q, Jiang F, Pins M, Kozlowski JM, Wang Z. Suppression of prostate tumor growth by U19, a novel testosterone-regulated apoptosis inducer. Cancer Res 2003; 63(15):4698-4704. (Pubitemid 36951050)
27. Rozen S, Skaletsky H. Primer3. Bioinformatics methods and protocols: Methods in molecular biology, Vol.2000. Totowa: Humana Press; 2000. p Primer3 on WWW for general users and for biologist programmers.
28. Livak K. ABI Prism 7700 Sequence Detection System User Bulletin #2 Relative quantification of gene expression. ABI company publication 1997 & 2001.
29. Wang Z, Tufts R, Haleem R, Cai X. Genes regulated by androgen in the rat ventral prostate. Proc Natl Acad Sci USA 1997;94: 12999-13004. (Pubitemid 27518465)
30. Jiang F, Wang Z. Identification of androgen-responsive genes in the rat ventral prostate by complementary deoxyribonucleic acid subtraction and microarray. Endocrinology 2003;144(4):1257-1265. (Pubitemid 36428467)
31. Cunha G. Androgenic effects upon prostatic epithelium are mediated via trophic influences from stroma [Review]. Prog Clin Biol Res 1984;145:81-102.
32. Cunha GR, Chung LW, Shannon JM, Reese BA. Stromal-epithelial interactions in sex differentiation. Biol Reprod 1980; 22(1):19-42.
33. Nemeth JA, Zelner DJ, Lang S, Lee C. Keratinocyte growth factor in the rat ventral prostate: Androgen-independent expression. J Endocrinol 1998;156(1):115-125. (Pubitemid 28049871)
34. Irer B, Toylu A, Aslan G, Celebi I, Yorukoglu K, Atabey N. Increased expression of NKX3.1 in benign prostatic hyperplasia. Urology 2009;73(5):1140-1144.
35. Liu X, Wang L, Lin Y, Teng Q, Zhao C, Hu H, Chi W. Ornithine decarboxylase activity and its gene expression are increased in benign hyperplastic prostate. Prostate 2000;43(2):83-87. (Pubitemid 30220610)
36. Cyriac J, Haleem R, Cai X, Wang Z. Androgen regulation of spermidine synthase expression in the rat prostate. Prostate 2002;50(4):252-261. (Pubitemid 34184665)
37. Bowen C, Bubendorf L, Voeller HJ, Slack R, Willi N, Sauter G, Gasser TC, Koivisto P, Lack EE, Kononen J, Kallioniemi OP, Gelmann EP. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res 2000; 60(21):6111-6115. (Pubitemid 30839644)
38. Xu LL, Shi Y, Petrovics G, Sun C, Makarem M, Zhang W, Sesterhenn IA, McLeod DG, Sun L, Moul JW, Srivastava S. PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression. Cancer Res 2003;63(15): 4299-4304. (Pubitemid 36950993)
39. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007;39(1): 41-51. (Pubitemid 46026500)
40. Culig Z. Androgen receptor cross-talk with cell signalling pathways. Growth Factors 2004;22(3):179-184. (Pubitemid 39377910)
41. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994;54(20):5474-5478. (Pubitemid 24978134)
42. Debes JD, Schmidt LJ, Huang H, Tindall DJ. p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res 2002;62(20):5632-5636. (Pubitemid 35204712)
43. Ueda T, Mawji NR, Bruchovsky N, Sadar MD. Ligand-independent activation of the androgen receptor by interleukin- 6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem 2002;277(41):38087-38094. (Pubitemid 35157768)
44. Lee SO, Chun JY, Nadiminty N, Lou W, Gao AC. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate 2007;67(7):764-773. (Pubitemid 46709445)
45. Lee SO, Lou W, Hou M, de Miguel F, Gerber L, Gao AC. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res 2003; 9(1):370-376. (Pubitemid 36109754)
46. Lee SO, Pinder E, Chun JY, Lou W, Sun M, Gao AC. Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells. Prostate 2008;68(1):85-91.
47. Lee LF, Louie MC, Desai SJ, Yang J, Chen HW, Evans CP, Kung HJ. Interleukin-8 confers androgen-independent growth and migration of LNCaP: Differential effects of tyrosine kinases Src and FAK. Oncogene 2004;23(12):2197-2205. (Pubitemid 38482534)
48. Hayes SA, Zarnegar M, Sharma M, Yang F, Peehl DM, ten Dijke P, Sun Z. SMAD3 represses androgen receptor-mediated transcription. Cancer Res 2001;61(5):2112-2118.
49. Kang HY, Lin HK, Hu YC, Yeh S, Huang KE, Chang C. From transforming growth factor-beta signaling to androgen action: Identification of Smad3 as an androgen receptor coregulator in prostate cancer cells. Proc Natl Acad Sci USA 2001;98(6): 3018-3023. (Pubitemid 32220792)
50. Jin RJ, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L, Case TC, Ellwood-Yen K, Sawyers CL, Bhowmick NA, Blackwell TS, Yull FE, Matusik RJ. The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res 2008;68(16):6762-6769.
51. Luo J, Dunn TA, Ewing CM, Walsh PC, Isaacs WB. Decreased gene expression of steroid 5 alpha-reductase 2 inhuman prostate cancer: Implications for finasteride therapy of prostate carcinoma. Prostate 2003;57(2):134-139. (Pubitemid 37204494)